Browsing Tag
CD20
1 post
Candid Therapeutics launches first-in-class T-cell engager trials across five autoimmune diseases
Candid Therapeutics begins Phase 1 trials of BCMA and CD20 T-cell engagers across five autoimmune diseases; institutional interest builds around TCE approach.